Market Research Report
Cathepsin L1 - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||398833|
|Published||Content info||33 Pages
Delivery time: 1-2 business days
|Cathepsin L1 - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 33 Pages||
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 184.108.40.206) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 220.127.116.11) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Infectious Disease, Gastrointestinal and Immunology which include indications Autoimmune Disorders, Breast Cancer, Cancer Pain, Coronavirus Disease 2019 (COVID-19), Head And Neck Cancer Squamous Cell Carcinoma, Liver Fibrosis, Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Neuropathic Pain (Neuralgia), Osteosarcoma, Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Severe Acute Respiratory Syndrome (SARS).
The latest report Cathepsin L1 - Pipeline Review, H1 2020, outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.